Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BEN domain-containing protein 6 (BEND6) is a nuclear co-repressor that binds the CSL transcription factor (CBF1/RBPJ) and antagonizes Notch-dependent gene activation, thereby inhibiting Notch-mediated self-renewal and promoting neural differentiation. It acts analogously to the *Drosophila* Insensitive protein as a BEN-solo factor regulating neural cell fate, and is thought to fine-tune Notch signaling during embryonic brain development. BEND6 is predicted to act within the nucleus, regulating chromatin and gene expression relevant to neural stem cell differentiation. Diseases associated include Carpenter syndrome 1, and while it modulates pathways central to neurodevelopment, it is not currently known to be a direct target of approved drugs[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BEN domain-containing protein 6 (BEND6).